Form 4: Mirum Pharmaceuticals Director Timothy Walbert Acquires Stock Options and Restricted Stock Units

Director Timothy Walbert reports acquisition of stock options and restricted stock units in Mirum Pharmaceuticals.

Summary

• On June 5, 2024, Timothy Walbert, a director at Mirum Pharmaceuticals, acquired 8,779 stock options with an exercise price of $26.30.
• These options vest on the first anniversary of the grant date but will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Walbert also acquired 5,703 restricted stock units (RSUs), each representing a contingent right to receive one share of Mirum Pharmaceuticals' common stock.
• These RSUs also vest on the first anniversary of the grant date and will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Following these transactions, Walbert directly owns 8,779 stock options and 5,703 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock options and restricted stock units granted to a director. The vesting schedule and exercise price are typical.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director can positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates